Search research articles
Contact Us
Filters
Showing results (41-50 of 67) with videos related to
Page
of 7
Sort By:
Journal of Gastrointestinal Oncology
|
January 5, 2018
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramesh K Ramanathan, Glen J Weiss, Richard G Posner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 7, 2011
Advancing a clinically relevant perspective of the clonal nature of cancer
Christian Ruiz, Elizabeth Lenkiewicz, Lisa Evers, et al.
JAMA Oncology
|
October 4, 2019
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial
Gayle S Jameson, Erkut Borazanci, Hani M Babiker, et al.
Redox Biology
|
November 6, 2025
Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer
Gayle S Jameson, S Danielle LeGrand, Michael S Gordon, et al.
Oncotarget
|
April 19, 2017
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma
Priscila H Goncalves, Lance K Heilbrun, Michael T Barrett, et al.
Plos One
|
December 11, 2012
Deep clonal profiling of formalin fixed paraffin embedded clinical samples
Tara Holley, Elizabeth Lenkiewicz, Lisa Evers, et al.
Annals of Surgical Oncology
|
September 19, 2013
Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype
Lee J McGhan, Ann E McCullough, Cheryl A Protheroe, et al.
Cancer Chemotherapy and Pharmacology
|
May 23, 2020
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer
Mansi Arora, James M Bogenberger, Amro Abdelrahman, et al.
Plos One
|
February 8, 2014
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements
Jan B Egan, Michael T Barrett, Mia D Champion, et al.
Molecular Cancer Therapeutics
|
March 5, 2024
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
Adam M Kase, Justyna Gleba, James L Miller, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 67) with videos related to
Sort By:
Page
of 7
Journal of Gastrointestinal Oncology
|
January 5, 2018
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramesh K Ramanathan, Glen J Weiss, Richard G Posner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 7, 2011
Advancing a clinically relevant perspective of the clonal nature of cancer
Christian Ruiz, Elizabeth Lenkiewicz, Lisa Evers, et al.
JAMA Oncology
|
October 4, 2019
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial
Gayle S Jameson, Erkut Borazanci, Hani M Babiker, et al.
Redox Biology
|
November 6, 2025
Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer
Gayle S Jameson, S Danielle LeGrand, Michael S Gordon, et al.
Oncotarget
|
April 19, 2017
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma
Priscila H Goncalves, Lance K Heilbrun, Michael T Barrett, et al.
Plos One
|
December 11, 2012
Deep clonal profiling of formalin fixed paraffin embedded clinical samples
Tara Holley, Elizabeth Lenkiewicz, Lisa Evers, et al.
Annals of Surgical Oncology
|
September 19, 2013
Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype
Lee J McGhan, Ann E McCullough, Cheryl A Protheroe, et al.
Cancer Chemotherapy and Pharmacology
|
May 23, 2020
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer
Mansi Arora, James M Bogenberger, Amro Abdelrahman, et al.
Plos One
|
February 8, 2014
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements
Jan B Egan, Michael T Barrett, Mia D Champion, et al.
Molecular Cancer Therapeutics
|
March 5, 2024
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
Adam M Kase, Justyna Gleba, James L Miller, et al.
Page
of 7